Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Background Patients with cancer are considered a priority group for Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of …

Patients with hematological malignancies are at increased risk of severe COVID-19
outcomes due to compromised immune responses, but the insights of these studies have …

Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID …

Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et
al., 2020), and they are currently prioritized globally for a third COVID-19 vaccine dose …

Vaccines developed against SARS-CoV-2 have proven to be highly effective in preventing
symptomatic infection. Similarly, prior infection with SARS-CoV-2 has been shown to provide …

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the
prospective CAPTURE study, integrating longitudinal immune profiling with clinical …

Purpose To evaluate the immunogenicity of COVID-19 vaccines in patients with diabetes
mellitus (DM) through a systematic approach. Method A comprehensive search was …

Resident memory T cells (TRM) present at the respiratory tract may be essential to enhance
early SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term …